Host factors are more important in predicting recurrent Clostridium difficile infection than ribotype and use of antibiotics

A frequent complication of Clostridium difficile infection (CDI) is recurrent disease. The aim of this study was to determine whether early recurrence risk was higher after infection with ribotype 027 (outbreak strain) compared with infection with endemic strain types of C. difficile. Consecutive pa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical microbiology and infection 2018-01, Vol.24 (1), p.85.e1-85.e4
Hauptverfasser: van Beurden, Y.H., Nezami, S., Mulder, C.J.J., Vandenbroucke-Grauls, C.M.J.E.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 85.e4
container_issue 1
container_start_page 85.e1
container_title Clinical microbiology and infection
container_volume 24
creator van Beurden, Y.H.
Nezami, S.
Mulder, C.J.J.
Vandenbroucke-Grauls, C.M.J.E.
description A frequent complication of Clostridium difficile infection (CDI) is recurrent disease. The aim of this study was to determine whether early recurrence risk was higher after infection with ribotype 027 (outbreak strain) compared with infection with endemic strain types of C. difficile. Consecutive patients diagnosed with CDI between May 2013 and March 2014 were included (outbreak strain, and non-outbreak strains). Patients who developed recurrent CDI within 30 days after completion of CDI treatment, were compared with patients without a recurrence. Medical charts were reviewed for demographic and clinical characteristics. General practitioners were contacted to complete data about the occurrence of recurrent CDI, and the use of medication after hospital discharge. In total, 135 patients were at risk for the development of recurrent CDI; 74 patients were infected by ribotype 027, and 61 patients by other ribotypes. Thirty-nine patients (29%) developed recurrent CDI within 30 days after completion of CDI treatment. In multivariable analysis, age ≥70 years (HR 3.05, 95% CI 1.54–6.03), and a duration of CDI treatment ≥11 days (HR 1.92, 95% CI 1.00–3.69) were clearly associated with recurrence; infection with ribotype 027 showed a HR of 1.72 (95% CI 0.88–3.33). During this outbreak of C. difficile in a tertiary care centre, age and a prolonged duration of CDI therapy (which is most likely a marker of underlying disease severity) were the main risk factors for recurrent CDI. This points to host factors as more important predictors for recurrent CDI than strain type or antibiotic use.
doi_str_mv 10.1016/j.cmi.2017.07.025
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1926979962</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1198743X17304093</els_id><sourcerecordid>1926979962</sourcerecordid><originalsourceid>FETCH-LOGICAL-c396t-848a20d2f1b7045d88c2d8adb3ca7f9c0b72b567f748bde5898f5ee3c645c9b33</originalsourceid><addsrcrecordid>eNp9kE1rFTEUhgdRbK3-ADeSpZu5TTIfSXAlF7WFghsFdyEfJ3ouM8mYZISCP96UW10Kh-QQnveFPF33mtEDo2y-Ph3cigdOmTjQNnx60l2ycVY9nRV72namZC_G4dtF96KUE6WUD8P4vLvgUkg-j-Ky-32TSiXBuJpyISYDWVM7cN1SriZWgpFsGTy6ivE7yeD2nKG9H5cWzOhxX4nHENDh0nIxQCNTJPWHiSSjTfV-A2KiJ3sBkkJbK1pMFV152T0LZinw6vG-6r5-_PDleNPfff50e3x_17tBzbWXozSceh6YFXScvJSOe2m8HZwRQTlqBbfTLIIYpfUwSSXDBDC4eZycssNw1b099245_dyhVL1icbAsJkLai2aKz0ooNfOGsjPqciolQ9BbxtXke82ofpCuT7pJ1w_SNW3Dp5Z581i_2xX8v8Rfyw14dwagffIXQtbFIUTXtDahVfuE_6n_A7IClYo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1926979962</pqid></control><display><type>article</type><title>Host factors are more important in predicting recurrent Clostridium difficile infection than ribotype and use of antibiotics</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>van Beurden, Y.H. ; Nezami, S. ; Mulder, C.J.J. ; Vandenbroucke-Grauls, C.M.J.E.</creator><creatorcontrib>van Beurden, Y.H. ; Nezami, S. ; Mulder, C.J.J. ; Vandenbroucke-Grauls, C.M.J.E.</creatorcontrib><description>A frequent complication of Clostridium difficile infection (CDI) is recurrent disease. The aim of this study was to determine whether early recurrence risk was higher after infection with ribotype 027 (outbreak strain) compared with infection with endemic strain types of C. difficile. Consecutive patients diagnosed with CDI between May 2013 and March 2014 were included (outbreak strain, and non-outbreak strains). Patients who developed recurrent CDI within 30 days after completion of CDI treatment, were compared with patients without a recurrence. Medical charts were reviewed for demographic and clinical characteristics. General practitioners were contacted to complete data about the occurrence of recurrent CDI, and the use of medication after hospital discharge. In total, 135 patients were at risk for the development of recurrent CDI; 74 patients were infected by ribotype 027, and 61 patients by other ribotypes. Thirty-nine patients (29%) developed recurrent CDI within 30 days after completion of CDI treatment. In multivariable analysis, age ≥70 years (HR 3.05, 95% CI 1.54–6.03), and a duration of CDI treatment ≥11 days (HR 1.92, 95% CI 1.00–3.69) were clearly associated with recurrence; infection with ribotype 027 showed a HR of 1.72 (95% CI 0.88–3.33). During this outbreak of C. difficile in a tertiary care centre, age and a prolonged duration of CDI therapy (which is most likely a marker of underlying disease severity) were the main risk factors for recurrent CDI. This points to host factors as more important predictors for recurrent CDI than strain type or antibiotic use.</description><identifier>ISSN: 1198-743X</identifier><identifier>EISSN: 1469-0691</identifier><identifier>DOI: 10.1016/j.cmi.2017.07.025</identifier><identifier>PMID: 28782647</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Aged ; Aged, 80 and over ; Anti-Bacterial Agents - therapeutic use ; Clostridium difficile - classification ; Clostridium difficile - drug effects ; Clostridium difficile - isolation &amp; purification ; Clostridium Infections - diagnosis ; Clostridium Infections - drug therapy ; Clostridium Infections - epidemiology ; Cross Infection - epidemiology ; Cross Infection - microbiology ; Disease Outbreaks ; Female ; Host factors ; Humans ; Male ; Netherlands - epidemiology ; Outbreak ; Recurrence ; Recurrent Clostridium difficile infection (CDI) ; Ribotype 027 ; Ribotyping ; Risk Factors ; Tertiary Care Centers</subject><ispartof>Clinical microbiology and infection, 2018-01, Vol.24 (1), p.85.e1-85.e4</ispartof><rights>2017 European Society of Clinical Microbiology and Infectious Diseases</rights><rights>Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c396t-848a20d2f1b7045d88c2d8adb3ca7f9c0b72b567f748bde5898f5ee3c645c9b33</citedby><cites>FETCH-LOGICAL-c396t-848a20d2f1b7045d88c2d8adb3ca7f9c0b72b567f748bde5898f5ee3c645c9b33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28782647$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van Beurden, Y.H.</creatorcontrib><creatorcontrib>Nezami, S.</creatorcontrib><creatorcontrib>Mulder, C.J.J.</creatorcontrib><creatorcontrib>Vandenbroucke-Grauls, C.M.J.E.</creatorcontrib><title>Host factors are more important in predicting recurrent Clostridium difficile infection than ribotype and use of antibiotics</title><title>Clinical microbiology and infection</title><addtitle>Clin Microbiol Infect</addtitle><description>A frequent complication of Clostridium difficile infection (CDI) is recurrent disease. The aim of this study was to determine whether early recurrence risk was higher after infection with ribotype 027 (outbreak strain) compared with infection with endemic strain types of C. difficile. Consecutive patients diagnosed with CDI between May 2013 and March 2014 were included (outbreak strain, and non-outbreak strains). Patients who developed recurrent CDI within 30 days after completion of CDI treatment, were compared with patients without a recurrence. Medical charts were reviewed for demographic and clinical characteristics. General practitioners were contacted to complete data about the occurrence of recurrent CDI, and the use of medication after hospital discharge. In total, 135 patients were at risk for the development of recurrent CDI; 74 patients were infected by ribotype 027, and 61 patients by other ribotypes. Thirty-nine patients (29%) developed recurrent CDI within 30 days after completion of CDI treatment. In multivariable analysis, age ≥70 years (HR 3.05, 95% CI 1.54–6.03), and a duration of CDI treatment ≥11 days (HR 1.92, 95% CI 1.00–3.69) were clearly associated with recurrence; infection with ribotype 027 showed a HR of 1.72 (95% CI 0.88–3.33). During this outbreak of C. difficile in a tertiary care centre, age and a prolonged duration of CDI therapy (which is most likely a marker of underlying disease severity) were the main risk factors for recurrent CDI. This points to host factors as more important predictors for recurrent CDI than strain type or antibiotic use.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Clostridium difficile - classification</subject><subject>Clostridium difficile - drug effects</subject><subject>Clostridium difficile - isolation &amp; purification</subject><subject>Clostridium Infections - diagnosis</subject><subject>Clostridium Infections - drug therapy</subject><subject>Clostridium Infections - epidemiology</subject><subject>Cross Infection - epidemiology</subject><subject>Cross Infection - microbiology</subject><subject>Disease Outbreaks</subject><subject>Female</subject><subject>Host factors</subject><subject>Humans</subject><subject>Male</subject><subject>Netherlands - epidemiology</subject><subject>Outbreak</subject><subject>Recurrence</subject><subject>Recurrent Clostridium difficile infection (CDI)</subject><subject>Ribotype 027</subject><subject>Ribotyping</subject><subject>Risk Factors</subject><subject>Tertiary Care Centers</subject><issn>1198-743X</issn><issn>1469-0691</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1rFTEUhgdRbK3-ADeSpZu5TTIfSXAlF7WFghsFdyEfJ3ouM8mYZISCP96UW10Kh-QQnveFPF33mtEDo2y-Ph3cigdOmTjQNnx60l2ycVY9nRV72namZC_G4dtF96KUE6WUD8P4vLvgUkg-j-Ky-32TSiXBuJpyISYDWVM7cN1SriZWgpFsGTy6ivE7yeD2nKG9H5cWzOhxX4nHENDh0nIxQCNTJPWHiSSjTfV-A2KiJ3sBkkJbK1pMFV152T0LZinw6vG-6r5-_PDleNPfff50e3x_17tBzbWXozSceh6YFXScvJSOe2m8HZwRQTlqBbfTLIIYpfUwSSXDBDC4eZycssNw1b099245_dyhVL1icbAsJkLai2aKz0ooNfOGsjPqciolQ9BbxtXke82ofpCuT7pJ1w_SNW3Dp5Z581i_2xX8v8Rfyw14dwagffIXQtbFIUTXtDahVfuE_6n_A7IClYo</recordid><startdate>201801</startdate><enddate>201801</enddate><creator>van Beurden, Y.H.</creator><creator>Nezami, S.</creator><creator>Mulder, C.J.J.</creator><creator>Vandenbroucke-Grauls, C.M.J.E.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201801</creationdate><title>Host factors are more important in predicting recurrent Clostridium difficile infection than ribotype and use of antibiotics</title><author>van Beurden, Y.H. ; Nezami, S. ; Mulder, C.J.J. ; Vandenbroucke-Grauls, C.M.J.E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c396t-848a20d2f1b7045d88c2d8adb3ca7f9c0b72b567f748bde5898f5ee3c645c9b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Clostridium difficile - classification</topic><topic>Clostridium difficile - drug effects</topic><topic>Clostridium difficile - isolation &amp; purification</topic><topic>Clostridium Infections - diagnosis</topic><topic>Clostridium Infections - drug therapy</topic><topic>Clostridium Infections - epidemiology</topic><topic>Cross Infection - epidemiology</topic><topic>Cross Infection - microbiology</topic><topic>Disease Outbreaks</topic><topic>Female</topic><topic>Host factors</topic><topic>Humans</topic><topic>Male</topic><topic>Netherlands - epidemiology</topic><topic>Outbreak</topic><topic>Recurrence</topic><topic>Recurrent Clostridium difficile infection (CDI)</topic><topic>Ribotype 027</topic><topic>Ribotyping</topic><topic>Risk Factors</topic><topic>Tertiary Care Centers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van Beurden, Y.H.</creatorcontrib><creatorcontrib>Nezami, S.</creatorcontrib><creatorcontrib>Mulder, C.J.J.</creatorcontrib><creatorcontrib>Vandenbroucke-Grauls, C.M.J.E.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical microbiology and infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van Beurden, Y.H.</au><au>Nezami, S.</au><au>Mulder, C.J.J.</au><au>Vandenbroucke-Grauls, C.M.J.E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Host factors are more important in predicting recurrent Clostridium difficile infection than ribotype and use of antibiotics</atitle><jtitle>Clinical microbiology and infection</jtitle><addtitle>Clin Microbiol Infect</addtitle><date>2018-01</date><risdate>2018</risdate><volume>24</volume><issue>1</issue><spage>85.e1</spage><epage>85.e4</epage><pages>85.e1-85.e4</pages><issn>1198-743X</issn><eissn>1469-0691</eissn><abstract>A frequent complication of Clostridium difficile infection (CDI) is recurrent disease. The aim of this study was to determine whether early recurrence risk was higher after infection with ribotype 027 (outbreak strain) compared with infection with endemic strain types of C. difficile. Consecutive patients diagnosed with CDI between May 2013 and March 2014 were included (outbreak strain, and non-outbreak strains). Patients who developed recurrent CDI within 30 days after completion of CDI treatment, were compared with patients without a recurrence. Medical charts were reviewed for demographic and clinical characteristics. General practitioners were contacted to complete data about the occurrence of recurrent CDI, and the use of medication after hospital discharge. In total, 135 patients were at risk for the development of recurrent CDI; 74 patients were infected by ribotype 027, and 61 patients by other ribotypes. Thirty-nine patients (29%) developed recurrent CDI within 30 days after completion of CDI treatment. In multivariable analysis, age ≥70 years (HR 3.05, 95% CI 1.54–6.03), and a duration of CDI treatment ≥11 days (HR 1.92, 95% CI 1.00–3.69) were clearly associated with recurrence; infection with ribotype 027 showed a HR of 1.72 (95% CI 0.88–3.33). During this outbreak of C. difficile in a tertiary care centre, age and a prolonged duration of CDI therapy (which is most likely a marker of underlying disease severity) were the main risk factors for recurrent CDI. This points to host factors as more important predictors for recurrent CDI than strain type or antibiotic use.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>28782647</pmid><doi>10.1016/j.cmi.2017.07.025</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1198-743X
ispartof Clinical microbiology and infection, 2018-01, Vol.24 (1), p.85.e1-85.e4
issn 1198-743X
1469-0691
language eng
recordid cdi_proquest_miscellaneous_1926979962
source MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Aged
Aged, 80 and over
Anti-Bacterial Agents - therapeutic use
Clostridium difficile - classification
Clostridium difficile - drug effects
Clostridium difficile - isolation & purification
Clostridium Infections - diagnosis
Clostridium Infections - drug therapy
Clostridium Infections - epidemiology
Cross Infection - epidemiology
Cross Infection - microbiology
Disease Outbreaks
Female
Host factors
Humans
Male
Netherlands - epidemiology
Outbreak
Recurrence
Recurrent Clostridium difficile infection (CDI)
Ribotype 027
Ribotyping
Risk Factors
Tertiary Care Centers
title Host factors are more important in predicting recurrent Clostridium difficile infection than ribotype and use of antibiotics
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T01%3A58%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Host%20factors%20are%20more%20important%20in%20predicting%20recurrent%20Clostridium%20difficile%20infection%20than%20ribotype%20and%20use%20of%20antibiotics&rft.jtitle=Clinical%20microbiology%20and%20infection&rft.au=van%20Beurden,%20Y.H.&rft.date=2018-01&rft.volume=24&rft.issue=1&rft.spage=85.e1&rft.epage=85.e4&rft.pages=85.e1-85.e4&rft.issn=1198-743X&rft.eissn=1469-0691&rft_id=info:doi/10.1016/j.cmi.2017.07.025&rft_dat=%3Cproquest_cross%3E1926979962%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1926979962&rft_id=info:pmid/28782647&rft_els_id=S1198743X17304093&rfr_iscdi=true